Click for best price
Kidney Cancer Renal Cell Carcinoma RCC Drugs Market Size, Share 2022
Kidney cancer/ renal cell carcinoma (RCC) is among ten most commonly observed cancer these days. It is sixth common cancer observed in men and it is the tenth most common cause of cancer for women.
This report contains market size and forecasts of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs in Global, including the following market information:
The global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs market was valued at 5255.3 million in 2021 and is projected to reach US$ 6545.8 million by 2028, at a CAGR of 3.2% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Afinitor (Everolimus) Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs include Active Biotech Ab, Amgen, Bayer AG, Cipla Limited, Roche Holding AG, Glaxosmithkline Plc, Novartis Ag and Pfizer, Inc. , etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Segment Percentages, by Type, 2021 (%)
- Afinitor (Everolimus)
- Avastin (Bevacizumab)
- Cabomety (Cabozantinib)
- Inlyta (Axitinib)
- Nexavar (Sorafenib)
- Proleukin (Aldesleukin)
- Torisel (Temsirolimus)
- Sutent (Sunitinib)
- Votrient (Pazopanib)
Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Segment Percentages, by Application, 2021 (%)
Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Segment Percentages, By Region and Country, 2021 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs revenues in global market, 2017-2022 (estimated), ($ millions)
- Key companies Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Active Biotech Ab
- Amgen
- Bayer AG
- Cipla Limited
- Roche Holding AG
- Glaxosmithkline Plc
- Novartis Ag
- Pfizer, Inc.
| Report Attributes |
Report Details |
| Report Title |
Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market - Global Outlook and Forecast 2022-2028 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
62 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Overall Market Size
2.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size: 2021 VS 2028
2.2 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Players in Global Market
3.2 Top Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Companies Ranked by Revenue
3.3 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue by Companies
3.4 Top 3 and Top 5 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Companies in Global Market, by Revenue in 2021
3.5 Global Companies Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product Type
3.6 Tier 1, Tier 2 and Tier 3 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Players in Global Market
3.6.1 List of Global Tier 1 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Companies
3.6.2 List of Global Tier 2 and Tier 3 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Markets, 2021 & 2028
4.1.2 Afinitor (Everolimus)
4.1.3 Avastin (Bevacizumab)
4.1.4 Cabomety (Cabozantinib)
4.1.5 Inlyta (Axitinib)
4.1.6 Nexavar (Sorafenib)
4.1.7 Proleukin (Aldesleukin)
4.1.8 Torisel (Temsirolimus)
4.1.9 Sutent (Sunitinib)
4.1.10 Votrient (Pazopanib)
4.2 By Type - Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue & Forecasts
4.2.1 By Type - Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, 2017-2022
4.2.2 By Type - Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, 2023-2028
4.2.3 By Type - Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, 2021 & 2028
5.1.2 Hospitals
5.1.3 Clinic
5.1.4 Others
5.2 By Application - Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue & Forecasts
5.2.1 By Application - Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, 2017-2022
5.2.2 By Application - Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, 2023-2028
5.2.3 By Application - Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region - Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, 2021 & 2028
6.2 By Region - Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue & Forecasts
6.2.1 By Region - Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, 2017-2022
6.2.2 By Region - Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, 2023-2028
6.2.3 By Region - Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, 2017-2028
6.3.2 US Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, 2017-2028
6.3.3 Canada Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, 2017-2028
6.3.4 Mexico Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, 2017-2028
6.4.2 Germany Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, 2017-2028
6.4.3 France Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, 2017-2028
6.4.4 U.K. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, 2017-2028
6.4.5 Italy Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, 2017-2028
6.4.6 Russia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, 2017-2028
6.4.7 Nordic Countries Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, 2017-2028
6.4.8 Benelux Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, 2017-2028
6.5.2 China Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, 2017-2028
6.5.3 Japan Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, 2017-2028
6.5.4 South Korea Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, 2017-2028
6.5.5 Southeast Asia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, 2017-2028
6.5.6 India Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, 2017-2028
6.6.2 Brazil Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, 2017-2028
6.6.3 Argentina Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, 2017-2028
6.7.2 Turkey Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, 2017-2028
6.7.3 Israel Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, 2017-2028
6.7.4 Saudi Arabia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, 2017-2028
6.7.5 UAE Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, 2017-2028
7 Players Profiles
7.1 Active Biotech Ab
7.1.1 Active Biotech Ab Corporate Summary
7.1.2 Active Biotech Ab Business Overview
7.1.3 Active Biotech Ab Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Major Product Offerings
7.1.4 Active Biotech Ab Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue in Global Market (2017-2022)
7.1.5 Active Biotech Ab Key News
7.2 Amgen
7.2.1 Amgen Corporate Summary
7.2.2 Amgen Business Overview
7.2.3 Amgen Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Major Product Offerings
7.2.4 Amgen Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue in Global Market (2017-2022)
7.2.5 Amgen Key News
7.3 Bayer AG
7.3.1 Bayer AG Corporate Summary
7.3.2 Bayer AG Business Overview
7.3.3 Bayer AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Major Product Offerings
7.3.4 Bayer AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue in Global Market (2017-2022)
7.3.5 Bayer AG Key News
7.4 Cipla Limited
7.4.1 Cipla Limited Corporate Summary
7.4.2 Cipla Limited Business Overview
7.4.3 Cipla Limited Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Major Product Offerings
7.4.4 Cipla Limited Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue in Global Market (2017-2022)
7.4.5 Cipla Limited Key News
7.5 Roche Holding AG
7.5.1 Roche Holding AG Corporate Summary
7.5.2 Roche Holding AG Business Overview
7.5.3 Roche Holding AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Major Product Offerings
7.5.4 Roche Holding AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue in Global Market (2017-2022)
7.5.5 Roche Holding AG Key News
7.6 Glaxosmithkline Plc
7.6.1 Glaxosmithkline Plc Corporate Summary
7.6.2 Glaxosmithkline Plc Business Overview
7.6.3 Glaxosmithkline Plc Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Major Product Offerings
7.6.4 Glaxosmithkline Plc Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue in Global Market (2017-2022)
7.6.5 Glaxosmithkline Plc Key News
7.7 Novartis Ag
7.7.1 Novartis Ag Corporate Summary
7.7.2 Novartis Ag Business Overview
7.7.3 Novartis Ag Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Major Product Offerings
7.7.4 Novartis Ag Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue in Global Market (2017-2022)
7.7.5 Novartis Ag Key News
7.8 Pfizer, Inc.
7.8.1 Pfizer, Inc. Corporate Summary
7.8.2 Pfizer, Inc. Business Overview
7.8.3 Pfizer, Inc. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Major Product Offerings
7.8.4 Pfizer, Inc. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue in Global Market (2017-2022)
7.8.5 Pfizer, Inc. Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Opportunities & Trends in Global Market
Table 2. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Drivers in Global Market
Table 3. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Restraints in Global Market
Table 4. Key Players of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs in Global Market
Table 5. Top Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Share by Companies, 2017-2022
Table 8. Global Companies Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product Type
Table 9. List of Global Tier 1 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type ? Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application ? Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region ? Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2023-2028
Table 30. Active Biotech Ab Corporate Summary
Table 31. Active Biotech Ab Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product Offerings
Table 32. Active Biotech Ab Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (US$, Mn), (2017-2022)
Table 33. Amgen Corporate Summary
Table 34. Amgen Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product Offerings
Table 35. Amgen Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (US$, Mn), (2017-2022)
Table 36. Bayer AG Corporate Summary
Table 37. Bayer AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product Offerings
Table 38. Bayer AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (US$, Mn), (2017-2022)
Table 39. Cipla Limited Corporate Summary
Table 40. Cipla Limited Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product Offerings
Table 41. Cipla Limited Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (US$, Mn), (2017-2022)
Table 42. Roche Holding AG Corporate Summary
Table 43. Roche Holding AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product Offerings
Table 44. Roche Holding AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (US$, Mn), (2017-2022)
Table 45. Glaxosmithkline Plc Corporate Summary
Table 46. Glaxosmithkline Plc Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product Offerings
Table 47. Glaxosmithkline Plc Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (US$, Mn), (2017-2022)
Table 48. Novartis Ag Corporate Summary
Table 49. Novartis Ag Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product Offerings
Table 50. Novartis Ag Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (US$, Mn), (2017-2022)
Table 51. Pfizer, Inc. Corporate Summary
Table 52. Pfizer, Inc. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product Offerings
Table 53. Pfizer, Inc. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (US$, Mn), (2017-2022)
List of Figures
Figure 1. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Segment by Type in 2021
Figure 2. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Segment by Application in 2021
Figure 3. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue in 2021
Figure 8. By Type - Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share, 2017-2028
Figure 9. By Application - Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share, 2017-2028
Figure 10. By Region - Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share, 2017-2028
Figure 11. By Country - North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share, 2017-2028
Figure 12. US Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share, 2017-2028
Figure 16. Germany Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2017-2028
Figure 17. France Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share, 2017-2028
Figure 24. China Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2017-2028
Figure 28. India Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share, 2017-2028
Figure 30. Brazil Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share, 2017-2028
Figure 33. Turkey Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, (US$, Mn), 2017-2028
Figure 37. Active Biotech Ab Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Amgen Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Bayer AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Cipla Limited Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Roche Holding AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Glaxosmithkline Plc Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Novartis Ag Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Pfizer, Inc. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
